CGON
CG Oncology Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -22.2% ·
share flow +30.0% ·
net new positions -20.0%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 7.01K | $443,642 | n/a | n/a |
| Q2 2026 | 94 | +7 | 45.65M | $3.24B | +12 | −5 |
| Q1 2026 | 90 | +11 | 42.64M | $2.85B | +15 | −4 |
| Q4 2025 | 77 | 0 | 47.85M | $1.99B | n/a | n/a |
| Q3 2025 | 16 | 0 | 30.32M | $1.22B | +1 | −1 |
| Q2 2025 | 13 | +1 | 24.41M | $634.75M | +2 | −1 |
| Q1 2025 | 9 | 0 | 12.23M | $299.43M | +1 | −1 |
| Q4 2024 | 9 | +1 | 9.32M | $267.32M | +1 | n/a |
| Q3 2024 | 7 | -2 | 3.66M | $137.92M | n/a | −2 |
| Q2 2024 | 9 | n/a | 2.48M | $78.32M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.08M | +96.2% | $40.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Point72 Asset Management ✦ | 746.06K | +575.7% | $28.15M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 591.41K | -11.1% | $22.31M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 510.22K | +153.4% | $19.25M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 5 | Adage Capital Partners ✦ | 400.00K | +21.2% | $15.09M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 321.36K | -34.6% | $12.13M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 7 | Marshall Wace ✦ | 7.70K | -89.9% | $290,521 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $1.36M | was 0.0% |
| Millennium Management | $412,683 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 232 holders, 86.28M shares, $5.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 500 sh · $30,825
Director · 500 sh · $31,240
Director · 1.00K sh · $72,980
Director · 1.00K sh · $74,540
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology